|1.||Jiang, Zhong: 13 articles (02/2007 - 07/2002)|
|2.||Isaacs, William B: 10 articles (07/2009 - 04/2002)|
|3.||Chinnaiyan, Arul M: 9 articles (06/2005 - 07/2002)|
|4.||Rubin, Mark A: 9 articles (06/2005 - 07/2002)|
|5.||Yang, Ximing J: 8 articles (10/2009 - 07/2002)|
|6.||Epstein, Jonathan I: 8 articles (07/2009 - 06/2003)|
|7.||Woda, Bruce A: 8 articles (09/2006 - 07/2002)|
|8.||Cheng, Liang: 7 articles (04/2014 - 02/2007)|
|9.||Martignoni, Guido: 5 articles (01/2010 - 06/2008)|
|10.||Gobbo, Stefano: 5 articles (01/2010 - 06/2008)|
|1.||Prostatic Neoplasms (Prostate Cancer)
09/15/2008 - "Sequence variants of alpha-methylacyl-CoA racemase are associated with prostate cancer risk: a replication study in an ethnically homogeneous population."
12/01/2005 - "Studies using a monoclonal (P504S) and a polyclonal antibody (p-AMACR) to alpha-methylacyl-CoA racemase (AMACR) have shown variable expression in prostate cancer (PCa). "
09/01/2004 - "Alpha-methylacyl-CoA racemase: a multi-institutional study of a new prostate cancer marker."
03/01/2004 - "This study uses the AQUA system to assess a recently described prostate cancer biomarker, alpha-methylacyl-CoA-racemase (AMACR), and to determine the effectiveness of the quantitative measurement of this marker as a means for making the diagnosis of prostate cancer. "
04/15/2002 - "In this study, we describe a gene, alpha-methylacyl-CoA racemase (AMACR), whose expression is consistently up-regulated in prostate cancer. "
|2.||Renal Cell Carcinoma (Grawitz Tumor)
01/01/2004 - "Expression of alpha-methylacyl-CoA racemase in papillary renal cell carcinoma."
09/01/2008 - "We conclude that Ulex europaeus agglutinin 1 reactivity and positivity for E-cadherin and c-KIT are effective in distinguishing collecting duct carcinoma from papillary renal cell carcinoma, and that negative results for alpha-methylacyl CoA racemase and CD10 are potentially useful hallmarks of this distinction also. "
01/01/2010 - "We performed fluorescent in situ hybridization (FISH) to investigate the numeric change of chromosomes 7, 17, and Y and loss of chromosome 3p in "papillary renal cell carcinomas (RCC) with extensive clear cell changes (CCC)." Consecutive cases of RCC over a 12-year period were reviewed to identify "papillary RCC with extensive CCC." Immunostaining for cytokeratin 7 and alpha-methylacyl-CoA racemase (AMACR) and FISH for chromosomes 7, 17, Y, and 3p were applied. "
09/01/2008 - "alpha-Methylacyl-CoA racemase (AMACR)/P504S has been reported to be positive in prostatic adenocarcinoma, papillary renal cell carcinoma, and gastrointestinal neoplasmas; however, it has never been studied in clear cell carcinoma of the lower urinary tract. "
07/01/2009 - "Our study demonstrates that tubulocystic carcinoma and collecting duct carcinoma have different expression profiles of selected genes, including vimentin, p53, and alpha methylacyl CoA racemase. "
05/01/2013 - "With the present study we aimed to compare the pattern of expression of MCT2 and alpha-methylacyl-CoA racemase (AMACR), in prostate carcinoma, PIN lesions, non-neoplastic prostate tissue, and normal prostate and compare their sensitivity and specificity. "
02/01/2007 - "alpha-methylacyl-CoA racemase expression may be substantially diminished or entirely lost in prostate carcinoma after hormonal therapy. "
09/01/2006 - "Alpha methylacyl-CoA-racemase (AMACR), also known as P504S, has been widely used as a positive marker for the diagnosis of prostate carcinoma in clinical practice. "
09/01/2006 - "Sensitivity of P504S/alpha-methylacyl-CoA racemase (AMACR) immunohistochemistry for the detection of prostate carcinoma on stored needle biopsies."
03/01/2006 - "Alpha-methylacyl-CoA racemase (AMACR/P504S) protein expression in urothelial carcinoma of the upper urinary tract correlates with tumour progression."
10/29/2015 - "Alpha-methylacyl-CoA racemase (AMACR) is over-expressed in many cancer types and can serve as a novel diagnostic biomarker. "
01/20/2015 - "We use of this technique to separate prostate tumor and benign cells in human prostate needle biopsies based on the expression levels of the tumor marker alpha-methylacyl-CoA racemase (AMACR). "
01/01/2015 - "Alpha-methylacyl-CoA racemase (AMACR), an intracellular enzyme involved in lipid metabolism, has emerged as an immunohistochemical marker for many types of cancer. "
04/01/2014 - "If a case is still considered atypical by a uropathology expert after negative basal cell staining, positive staining for alpha-methylacyl-CoA-racemase can help establish in 50% of these cases a definitive diagnosis of cancer."
07/01/2013 - "The role of alpha-methylacyl-CoA racemase (AMACR) in pathogenesis and diagnosis of different types of cancer has been investigated during last decade. "
01/01/2008 - "Alpha-methylacyl-CoA racemase expression is upregulated in gastric adenocarcinoma: a study of 249 cases."
01/01/2013 - "Alpha methylacyl-CoA racemase (AMACR) is a useful diagnostic marker for prostate adenocarcinoma. "
01/01/2013 - "Alpha methylacyl-CoA racemase (AMACR) in prostate adenocarcinomas from Japanese patients: is AMACR a "race"-dependent marker?"
12/01/2011 - "Alpha-methylacyl-CoA racemase (AMACR) is highly expressed in prostatic adenocarcinoma. "
02/01/2007 - "Alpha-methylacyl-CoA racemase (P504S)/34betaE12/p63 triple cocktail stain in prostatic adenocarcinoma after hormonal therapy."
|3.||Fatty Acids (Saturated Fatty Acids)
|4.||Prostate-Specific Antigen (Semenogelase)
|6.||Keratin-7 (Cytokeratin 7)
|8.||Biological Markers (Surrogate Marker)
|9.||Transcription Factors (Transcription Factor)
|2.||Prostatectomy (Retropubic Prostatectomy)